You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The assay is Guardant Health’s first commercially available product for clinical management of early-stage tumors and is initially focused on colorectal cancer.
Despite challenges related to the coronavirus pandemic, the Chinese precision oncology firm reported total quarterly revenues of RMB131.7 million ($20.2 million).
In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.
A UCLA-led team uncovered differences in DNA methylation patterns between patients with persistent and resolving methicillin-resistant Staphylococcus aureus infections.
The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.
The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.
In PNAS this week: placental expression risk scores for schizophrenia, ancient DNA-based analysis of human arrival in China, and more.
The Spanish firm also expects to release clinical data on its early-stage, next-generation sequencing-based colorectal cancer test in the first half of 2021.
By bringing together epigenomic profiles for hundreds of tissue samples, researchers mapped regulatory modules relevant to a range of tissue and disease types.
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.
NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
In Science this week: review discusses advances in liquid biopsies, and more.